Galectin Therapeutics Inc. (GALT)

Over the past six months, Galectin Therapeutics' stock has been impacted by several events. In December 2025, the FDA provided written feedback on belapectin, leading to a stock price drop. Concurrently, the company secured an additional credit line. The Q3 2025 earnings report in November 2025 showed a miss in EPS expectations. In March 2026, full-year 2025 results were reported, showing a narrower net loss. Also in March 2026, Henry Brem, M.D., was appointed to the Board of Directors, and the stock experienced increased trading volume and price movements.

Galectin Therapeutics Inc. does not generate revenue from product sales, so traditional demand seasonality is not applicable. The company's financial performance is driven by drug development progress, clinical trial results, regulatory milestones, and financing activities. Historically, February has been the strongest month for GALT stock, while October has been the weakest.

Galectin Therapeutics, Inc. (GALT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for chronic liver disease and cancer. Their lead drug, belapectin, is in Phase 2b/3 trials for MASH cirrhosis with portal hypertension and has received FDA Fast Track designation. The company is also exploring belapectin for skin conditions and cancer, and advancing oral galectin-3 inhibitors through a joint venture.

Galectin Therapeutics Inc. is headquartered in Norcross, Georgia, United States. Its common stock is traded on The Nasdaq Stock Market under the ticker symbol GALT. The company's stock is also listed on several European exchanges, including Frankfurt, Stuttgart, Munich, and Dusseldorf Stock Exchanges.

Galectin Therapeutics' reputation has been affected by regulatory interactions and an ongoing investigation. The FDA's feedback on belapectin and the subsequent investigation by Levi & Korsinsky impacted the company's reputation. The NAVIGATE trial results also created uncertainty regarding regulatory strategy.

Galectin Therapeutics Inc. has a mixed ownership structure. Individual investors own the largest share, followed by insiders, including Chairman Richard Uihlein. Institutional investors hold a notable percentage of the company's stock, with major shareholders including Vanguard Group Inc., Advisor Group Holdings, Inc., and BlackRock, Inc.